Contact the Editorial Desk

Editorial correspondence

Peptide Research Protocols welcomes correspondence on the research record: a citation quoted inaccurately, a regulatory reference that has gone out of date, or a peer-reviewed study about tesamorelin, MOTS-c or CJC-1295 that should be incorporated into the references page. Corrections that improve the accuracy of the digest are the most useful messages received, and every substantive note is read carefully.

The most actionable submissions specify three things: the page in question, the exact passage they address, and the supporting citation — a DOI or PubMed identifier wherever possible. That allows verification against the source directly.

Editorial mailbox: editors@peptideresearchprotocols.com

What this desk cannot do

So that correspondence is not left unanswered for the wrong reason, several things fall outside what this site can address. Peptide Research Protocols is a literature digest, not a clinic or a vendor, so the desk cannot:

• Advise on, recommend or comment on human use of any peptide discussed here.
• Suggest a dose, schedule or route of administration for any individual.
• Diagnose a condition or assess whether a published research finding applies to a particular person.
• Sell, source, recommend or help locate any compound from any supplier.
• Advise athletes subject to anti-doping rules on the use of these compounds — all three are WADA-prohibited, and several prohibitions are in- and out-of-competition.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed; the mailbox is monitored intermittently.